Philina Lee
Director/Board Member bei FUSN PHAR
Vermögen: 3 Mio $ am 31.03.2024
Profil
Philina Lee is an Independent Director at Fusion Pharmaceuticals, Inc. since 2021.
She is also the Chief Commercial Officer at Blueprint Medicines Corp.
since 2014.
Previously, she worked at Algeta ASA as the Head-US Marketing.
Dr. Lee holds a doctorate degree from the Massachusetts Institute of Technology and an undergraduate degree from the University of Alberta.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 13.03.2024 | 34 729 ( 0,06% ) | 3 Mio $ | 31.03.2024 | |
| 14.06.2023 | 0 ( -.--% ) | - $ | 31.03.2024 |
Aktive Positionen von Philina Lee
| Unternehmen | Position | Beginn |
|---|---|---|
| FUSN PHAR | Director/Board Member | 11.02.2021 |
| BLUEPRINT MEDICINES CORPORATION | Corporate Officer/Principal | 01.01.2021 |
Ehemalige bekannte Positionen von Philina Lee
| Unternehmen | Position | Ende |
|---|---|---|
| ALGETA ASA | Corporate Officer/Principal | - |
Ausbildung von Philina Lee
| Massachusetts Institute of Technology | Doctorate Degree |
| University of Alberta | Undergraduate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| BLUEPRINT MEDICINES CORPORATION | Health Technology |
| FUSN PHAR | Health Technology |
| Private Unternehmen | 1 |
|---|---|
Algeta ASA
 Algeta ASA Pharmaceuticals: MajorHealth Technology Algeta ASA is engaged in the development of products for the treatment of cancer. The company focuses on the development of anti-cancer drugs, and its research and development of compounds focuses on the various applications of a few base compounds. Its products, Alpharadin and Thorium-227, are being developed for treatment of skeletal metastases originating from prostate and breast cancer. The company was founded by Roy H. Larsen and Øyvind Sverre Bruland in 1997 and is headquartered in Oslo, Norway. | Health Technology |
